Descripción de la empresa
Terns Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of small-molecule product candidates specifically designed for the treatment of oncology and obesity. Within the broader healthcare sector, the company functions in the biotechnology industry, a field characterized by significant research and development expenditures and high regulatory hurdles before products reach the market. The firm maintains a market capitalization of $5.98B and employs a workforce of 59 individuals, while its annual revenue figures are currently unavailable for reporting in the provided data. The substantial market capitalization relative to the lack of reported revenue and the small employee count indicates that the company's valuation is primarily driven by the potential future success of its pipeline assets rather than current operational earnings, reflecting a typical profile for early-to-mid-stage biotechnology firms where investor confidence is placed on clinical trial milestones rather than immediate profitability.
Salud financiera
The company reports a net income of $-94,435,000 and an EBITDA of $-108,331,000 over the trailing twelve months, while specific revenue figures are not disclosed in the available data. The significant negative gap between revenue and net income, combined with the absence of reported revenue, reveals a cost structure dominated by research and development expenses and other operating costs that far exceed current income generation capabilities. Free cash flow stands at $-51,270,876, which indicates that the company is burning cash to fund its clinical trials and operational activities, necessitating reliance on external capital sources or existing cash reserves for financial flexibility. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a common occurrence in clinical-stage development where costs are incurred without corresponding sales revenue to generate a positive margin percentage. The company holds a cash balance of $295.64M against a debt obligation of $1.03M, resulting in a debt-to-equity ratio of 0.36, which suggests a highly conservative balance sheet with minimal leverage despite the negative earnings. Additionally, the current ratio is exceptionally high at 19.52, indicating an abundance of current assets relative to current liabilities and providing a robust buffer against short-term liquidity pressures. Return on Equity is reported at -29.1% and Return on Assets at -19.9%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a standard characteristic of companies in the development phase of their product lifecycle.
Evaluación de valoración
The trailing twelve-month P/E ratio is not available due to the lack of positive earnings, while the forward P/E is listed as -44.26, implying that the market is pricing in future earnings expectations that have not yet been realized or are projected to be negative in the near term. The price-to-book ratio is 16.30, which indicates a significant market premium over the company's book value, suggesting that investors are valuing the company based on the potential of its intellectual property and pipeline rather than its tangible net assets. The price-to-sales ratio and EV/EBITDA are both unavailable or negative (-41.28), reflecting the company's pre-revenue status and negative earnings, which renders traditional valuation multiples less meaningful compared to clinical progress metrics. The stock has traded within a 52-week range with a high of $53.08 and a low of $1.86, placing the current valuation context within this wide historical band where the price is significantly closer to the upper bound relative to the lower bound. The beta is -0.29, a negative value that suggests the stock price moves inversely to the broader market or exhibits volatility patterns distinct from the overall market index, potentially acting as a hedge in certain portfolio constructions.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both unavailable in the provided data, preventing a direct comparison of growth rates between top-line sales and bottom-line earnings. As the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests all available resources and potential earnings into research and development activities rather than distributing income to shareholders. The absence of a dividend policy aligns with the company's lifecycle stage, where capital retention is prioritized to fund clinical trials and operational expansion rather than providing income to investors. Consequently, the overall growth and income profile is defined by a complete reliance on capital appreciation potential and the eventual commercialization of its oncology and obesity product candidates, with no current income stream or historical growth rate to reference.